Stocktoria
Axsome Therapeutics, Inc. AXSM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-19
Axsome Therapeutics, Inc. statistics & valuation
Market cap$12.4B
P / S19.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -26.1% | -72.7% | -85.7% | -359.3% | — |
| Net margin | -28.7% | -74.5% | -88.4% | -374.0% | — |
| FCF margin | -14.7% | -33.4% | -53.8% | -234.3% | — |
| Return on assets | -26.6% | -50.5% | -40.7% | -56.5% | -148.5% |
| Return on equity | -207.5% | -503.8% | -125.3% | -170.8% | -834.3% |
| Debt / equity | 1.33× | 3.17× | 0.93× | 0.86× | 3.14× |
| Current ratio | 1.55 | 2.11 | 3.63 | 2.54 | 3.75 |
| Revenue growth | 65.5% | 42.5% | 440.8% | — | — |
Source: SEC EDGAR filings · CIK 0001579428 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.